Background Oral fingolimod, a sphingosine-1-phosphate–receptor modulator that prevents
the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end …

… progressive multiple sclerosis … oral fingolimod or placebo for at least 36 months and a
maximum of 5 years. Patients were initially assigned to fingolimod 1·25 mg per day or placebo (…

… A placebo-controlled trial of oral fingolimod in relapsing … of clinical trials in multiple sclerosis
and other neurological diseases—the sponsoring pharmaceutical companies for these trials …

… models of multiple sclerosis, fingolimod … placebo-controlled, proof-of-concept clinical study
to evaluate the efficacy and safety of fingolimod for the treatment of relapsing multiple sclerosis…

… The oral immunomodulator laquinimod did not reach the … phase 3 trial of patients with relapsing
multiple sclerosis. In a phase 2 … from the controlled clinical trial setting to clinical practice. …

… direct comparator for both fingolimod 0.25 and 0.5 mg doses … placebo-controlled clinical
trial with a commercial product lacked equipoise. The primary results of the ASSESS clinical trial …

… Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS).
In the phase 3, 2-year FREEDOMS (… A placebo-controlled trial of oral fingolimod in relapsing …

… encephalomyelitis, an animal model of multiple sclerosis. In a 6-month, phase 2 study involving
patients with relapsing multiple sclerosis, 12 daily oral fingolimod at a dose of 5.0 or 1.25 …

Background: Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS)
relapses and disease progression. Common symptoms including depression and fatigue may …

… Evaluating effects of new treatments along with older immunomodulatory drugs with different
modes of action in relapsing-remitting MS (RRMS) patients in a controlled clinical trial may …